QB

Q-Line Biotech Ltd

Q2 FY27

Q-Line Biotech Q2 Results 2026 (FY27): Revenue ₹152 Cr, PAT ₹20 Cr

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Based on Q-Line Biotech Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹554
Market cap₹1.3K Cr
P/E22.8

The short version

H1 FY27 Revenue: Rs 152 crore, a 5.8% year-on-year (YoY) increase from Rs 144 crore in H1 FY26 (Page 8, 6). H1 FY27 Financials (Page 8 & 6):.

From Q-Line Biotech Ltd's Q2 FY27 earnings-call transcript · updated 13 Nov 2026.

How did Q-Line Biotech's revenue grow in the September 2026 quarter?

  • H1 FY27 Revenue: Rs 152 crore, a 5.8% year-on-year (YoY) increase from Rs 144 crore in H1 FY26 (Page 8, 6).
  • Revenue by segment H1 FY27: Instruments 21%, Reagents 72%, Consumables 6%, Services 1% (Page 7).
  • Reagent business growth: 19.23% growth during H1 FY27 (Page 5).
  • Instrument revenues: Declined 29.71% in H1 FY27, attributed to delayed government orders (Page 5).
  • Outlook:

2 more points from Q-Line Biotech Ltd's call on revenue

Create a free account to keep reading this call

What happened to Q-Line Biotech's margins in Q2 FY27?

See what Q-Line Biotech Ltd said on profitability & margins — free account, 30 seconds.

What capex is Q-Line Biotech planning?

  • Ramp up Unit 4 manufacturing facility towards full-scale operations in H2 FY27.
  • Product licenses for Unit 4 increased from 9 (Sept 30, 2026) to 36 (Nov 5, 2026).
  • Unit 4 expected to become fully operational during H2 FY27, supporting scale-up.
  • Capitalization of Unit 4 led to higher depreciation in H1 FY27.
  • Strategy includes acquisition of 70% stake in Heidelco Medicore for operational consolidation and resource utilization (status: proposed).

2 more points from Q-Line Biotech Ltd's call on capex

Create a free account to keep reading this call

Is Q-Line Biotech raising money or cutting debt?

See what Q-Line Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Q-Line Biotech's order book?

It does mention related operational aspects: - Instrument revenues declined by 29.71% in H1 FY27 primarily due to non-availability of consignees for certain government orders, which impacted order execution and delivery. - Government business remained stable compared with the corresponding period last year.

2 more points from Q-Line Biotech Ltd's call on order book

Create a free account to keep reading this call

What Q-Line Biotech's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Q-Line Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Q-Line Biotech Ltd Q2 FY27 results?

H1 FY27 Revenue: Rs 152 crore, a 5.8% year-on-year (YoY) increase from Rs 144 crore in H1 FY26 (Page 8, 6). H1 FY27 Financials (Page 8 & 6):.

What is Q-Line Biotech Ltd share price analysis?

Q-Line Biotech Ltd currently shows a neutral. The stock trades at a P/E of 22.8 with a market cap of ₹1,292 Cr. Investors should review the full earnings analysis for detailed insights.

Is Q-Line Biotech Ltd planning capital expenditure?

Ramp up Unit 4 manufacturing facility towards full-scale operations in H2 FY27.

Keep Q-Line Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.